Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
3 pending office actions • 2 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready
Shanghai Bao Pharmaceuticals Co. Ltd. is managing 4 pending office actions within the Chemistry & Materials technology area. These actions are distributed across 3 distinct examiners and 3 distinct art units, indicating some concentration of work despite the multiple pending matters. The involvement of 3 distinct art units suggests that the company's chemistry-related innovations are being evaluated by several specialized groups within the patent office.
The busiest examiner, FAN, LYNN Y, is responsible for 2 pending office actions, which represents half of the company's total pending workload. The remaining 2 pending office actions are split among the other 2 distinct examiners. This concentration suggests that FAN, LYNN Y is a primary point of contact within the 3 distinct art units involved. Practitioners should prioritize understanding the specific examination patterns of FAN, LYNN Y, as this individual's decisions will impact 2 of the 4 pending office actions currently facing the company.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FAN, LYNN Y | 2 | 47.3% | +49.5% |
| EDGINGTONGIORDANO, FRANCESCA | 1 | 70.8% | +31.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18291230 | ANTIBIOTIC PHARMACEUTICAL COMPOSITION CAPABLE OF SUBCUTANEOUS ADMINISTRATION | FAN, LYNN Y | — |
| 18260079 | RECOMBINANT HUMAN HYALURONIDASE FORMULATION AND APPLICATION THEREOF | FAN, LYNN Y | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18291230 | ANTIBIOTIC PHARMACEUTICAL COMPOSITION CAPABLE OF SUBCUTANEOUS ADMINISTRATION | FAN, LYNN Y | — |
| 18260079 | RECOMBINANT HUMAN HYALURONIDASE FORMULATION AND APPLICATION THEREOF | FAN, LYNN Y | — |
| 17593989 | ANTI-HER2 BISPECIFIC ANTIBODY AND APPLICATION THEREOF | EDGINGTONGIORDANO, FRANCESCA | — |
| Art Unit | Apps |
|---|---|
| 1759 | 2 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18291230 | ANTIBIOTIC PHARMACEUTICAL COMPOSITION CAPABLE OF SUBCUTANEOUS ADMINISTRATION | FAN, LYNN Y | 1759 | §101§102§103§112 | Non-Final OA | — | Pending | Jan 23, 2024 |
| 18260079 | RECOMBINANT HUMAN HYALURONIDASE FORMULATION AND APPLICATION THEREOF | FAN, LYNN Y | 1759 | §103§112 | Non-Final OA | — | Pending | Jun 30, 2023 |
| 17593989 | ANTI-HER2 BISPECIFIC ANTIBODY AND APPLICATION THEREOF | EDGINGTONGIORDANO, FRANCESCA | 1643 | §112 | Non-Final OA | — | Pending | Sep 29, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial